Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
about
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerAdoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergyQuercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development StrategyAlternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem CellsCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateUnderstanding the biology of melanoma and therapeutic implicationsComplete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsGenotyping of cutaneous melanoma.Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcomaDNA methylation subgroups in melanoma are associated with proliferative and immunological processesThe anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.Melanoma: Advances in Targeted Therapy and Molecular Markers.RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanomaConverting biology into clinical benefit: lessons learned from BRAF inhibitors.The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway.Overcoming resistance to BRAF inhibitors.Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes.Capsaicin: Friend or Foe in Skin Cancer and Other Related Malignancies?Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.Update on the clinical use of kinase inhibitors in melanoma.Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy
P2860
Q26747247-3290BD74-D9D0-4ED2-8E9C-A25330F68BDDQ26822793-3F4F43D1-D8DA-43FC-92D3-385ABC2DC2A3Q28076840-E3250523-9AFC-4A01-9358-849A627EDD76Q28084243-F87D80C5-9A3A-4744-ABA0-E8BC63A339A0Q30277902-1C683647-8E87-4E4C-B532-20A529F13558Q33887664-05EFFB8C-B5DE-4845-9397-717CB644A826Q33978378-18BA3578-03B3-4C2F-9FFE-729D55586934Q34438555-91ACF2CF-E091-43D0-A1F5-C904FA36D712Q34667738-74A01D96-5B0A-4F5D-BBBC-B3BC117FBC89Q34793401-7262C91B-8FD2-4160-A2C8-FA38D5386F10Q35834765-7B44E38D-3FC2-4B00-AEA7-FA0C132F44A1Q35856555-1C02F6CE-E630-4563-933C-42C09E6BCD87Q38148745-1D04AA58-D3F8-41FA-8D02-C86F0F90CC0FQ38557217-5C55760B-96D4-4604-89D4-C537B7E1F1B5Q38836377-F13F16DC-652B-4CC8-9E45-401D44CE07E7Q38940098-A3E0E4D1-C1EC-4C61-825E-CC58AC8F8E98Q38983353-24C0BC23-80A7-431F-99D3-E873C44B0A17Q39007220-BB148D82-1BE1-407B-8073-CDC636C361E3Q39029234-87646388-2DC3-4B37-BBBD-9DC8729ACC6AQ41354063-EFF836F3-694D-4648-ABD6-67C846FB60F9Q43298157-B1A2256C-792D-432B-91B0-A2F653F05F97Q47103159-7372B589-AC24-42DE-8E49-3235982D4FDEQ47162516-29B4F796-848F-4342-8542-3115A944E3ABQ47759599-14CA2E9E-BE22-4E82-9F3F-31B2C1D83CF0Q47965154-57F96BCE-077C-43F6-ACF6-C1B8E2E5E300Q57044361-ABAEFA2A-3BF2-4ADA-9439-A678AC0913B0
P2860
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
@en
type
label
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
@en
prefLabel
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
@en
P2860
P1476
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
@en
P2093
Lawrence N Kwong
Michael A Davies
P2860
P304
P356
10.1158/1078-0432.CCR-13-0142
P407
P577
2013-10-01T00:00:00Z